Clinical Trial Search

Primary: Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12 — -11.6; -62.6 percent change — p==0.039

Primary: Number of Participants Experiencing a Flare During Treatment Period 2 — 10; 21 Participants — p=<0.001

Primary: Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response — 100; 100; 100; 100 Percentage of Participants

Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study — 1 Participants

Primary: Percentage of Participants With Disease Flare in Part 2 — 81; 28 percentage of participants — p=0.0030

Primary: Percentage of Participants With an American College of Rheumatology Pediatric 30 (ACR Pedi 30) Response at Week 12 — 88.6 Percentage of participants

Primary: Normalized Net Incremental Area Under the Curve (AUC) for Patient Global Assessment of Disease Activity (PGA) Between Randomization and Week 12 — -28.54; -11.07 mm…

Primary: Disease Activity Score 28 (DAS28) at Month 12 — 4.56; 4.9 Units on a scale — p=<0.05

Primary: Percentage of Participants With Improvement of ≥ 0.50 Units From Baseline to Month 24 in the HAQ DI — 56.0 percentage of participants

Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055

Primary: Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) Between Randomization and Week 12 — -19.79…

Primary: Percentage of Participants Achieving Functional Remission Determined by Hannover Functional Ability Questionnaire (FFbH) at Week 26 — 36.4 percentage of participants

Primary: Number of Participants With Treatment-Related Adverse Events of Etanercept — 22 participants

Primary: Percentage of Participants Achieving Ankylosing Spondylitis (ASAS) 40 Response at Week 12 — 32.38; 15.74 Percentage of participants — p=0.0062

Primary: Percentage of Participants With 7 Years Adherence to Etanercept — 60.6 Percentage of participants

Primary: Primary: Participants With EULAR (Good) — 19 participants

Primary: Number (%) of Patients With Resolution of Achilles Tendon Enthesitis — 43; 32 Participants — p=0.136

Primary: Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24 — 44.3 percentage of participants

Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2

Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) — 287; 99 participants — p=<0.001

Primary: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Month 12 — 7.75; 7.74; 7.72; 7.78 Units on a scale — p=0.001

Primary: Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 — 194 Participants

Primary: Number of Participants With Treatment Related Adverse Events — 2 participants

Primary: Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Baseline — 30.18; 49.09; 53.06; 63.29 Percentage of impairment

Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01

Primary: Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR) — 3.0; 2.9; 3.1; 2.8 Scores on a scale

Primary: Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12 — 11.0; 57.0 percentage of participants…

Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml

Primary: Change From Baseline in Van Der Heijde Total Modified Total Sharp Score (mTSS) or Adapted mTSS at End of Phase 1 (Week 78): Efficacy Analysis Set (EAS) — 25.1; 14.7…

Primary: Percentage of Participants Achieving BASDAI 40 Response at Week 24 — 83.6 Percentage of participants